The short answer
Survodutide produced more average weight loss than placebo over 76 weeks. Digestive symptoms were common in both dose groups.
Who was studied?
This phase 3 trial randomized 725 adults with obesity or overweight plus a related complication, excluding diabetes. Everyone received lifestyle counseling.
Percent of starting weight; treatment-regimen estimand
Original visual based on the study.
| Group or measure | Result |
|---|---|
| Survodutide 3.6 mg | 12.2% |
| Survodutide 6.0 mg | 13.0% |
| Placebo | 5.4% |
What changed?
Average weight loss at week 76 was:
Survodutide 3.6 mg: 12.2%.
Survodutide 6.0 mg: 13.0%.
Placebo: 5.4%.
These estimates accounted for early treatment discontinuation and other specified treatment changes. They are group averages, not individual promises.
What were the trade-offs?
Digestive adverse events occurred in 80.9%, 89.7% and 47.9% of the respective groups. Most were mild or moderate. Those percentages describe symptoms, not the proportion who stopped treatment.
The useful takeaway
The trial supports a weight-loss effect for a medicine targeting both glucagon and GLP-1 receptors. It did not directly compare survodutide with semaglutide or tirzepatide. Separate-trial headlines cannot establish a winner.
Sources
le Roux and colleagues, New England Journal of Medicine, 2026. Funded by Boehringer Ingelheim.